situ, I think we are watching the beginning of the end of the generic competition in the US. If someone had been getting reimbursed for the generic through one of these companies it will stop. The big question I have is how long will it take for these changes to improve our weekly prescription numbers. Most investors won't understand the significance of the formulary changes. Even if they are aware of them. The generic companies are faced with a supply problem, and they are now loosing coverage for the supply that they have. One day investors will understand that Amarin will retain control of the US market. When that happens the share price will rise to reflect that. Sleven,
Market Data 
Markets 
